Proviron

Proviron Dragon Pharma — Overview

Proviron Dragon Pharma is mesterolone at 25 mg per tablet — a DHT-derived oral AAS used in performance protocols as a support compound rather than a primary anabolic driver. Mesterolone's defining pharmacological feature is its exceptionally high binding affinity for sex hormone-binding globulin (SHBG): by displacing testosterone from SHBG, it increases the free (biologically active) fraction of testosterone in circulation, effectively amplifying the androgenic and anabolic output of testosterone already present in the bloodstream. Combined with its mild anti-estrogenic properties and absence of aromatization, this makes Proviron a practical on-cycle addition for any testosterone-based protocol where libido maintenance, quality of muscle tissue, and estrogen management are priorities.

Unlike most oral AAS, mesterolone is not 17α-alkylated; it carries a 1-methyl group instead, which protects the molecule from hepatic inactivation without introducing the liver strain associated with alkylated orals. It produces no water retention, no aromatization, and only minimal HPTA suppression at standard doses of 25–75 mg/day. Proviron is available at Steroid Warehouse and is routinely used throughout bulking and cutting cycles to support libido, reduce SHBG-related testosterone binding, and contribute mild anti-estrogenic activity in dry stacks where an aromatase inhibitor would be excessive.

About the Compound: Mesterolone

Mesterolone is a 1-methylated derivative of dihydrotestosterone (DHT). The 1-methyl group serves the same function as 17α-alkylation does in other oral AAS — it slows hepatic inactivation, allowing the molecule to survive first-pass metabolism and reach systemic circulation orally — but without the liver toxicity that 17α-alkylation introduces. This makes mesterolone one of the few oral androgenic compounds that can be used for extended durations without the 6–8 week hepatic ceiling that limits most oral AAS.

As a DHT derivative, mesterolone does not aromatize to estradiol. It binds the androgen receptor with moderate affinity and carries a high binding affinity for SHBG — the plasma transport protein that binds and inactivates a significant fraction of circulating testosterone. At 25–75 mg/day, mesterolone occupies SHBG binding sites and displaces testosterone, increasing the ratio of free-to-total testosterone without changing total testosterone concentration. The clinical relevance is direct: more free testosterone is available to interact with androgen receptors in muscle, bone, and other target tissues. Mesterolone also exhibits weak aromatase inhibition, contributing a mild anti-estrogenic effect separate from its SHBG mechanism.

The oral half-life is approximately 12 hours, requiring twice-daily dosing (morning and evening) for consistent blood levels. At 25–50 mg/day, HPTA suppression is minimal because mesterolone is rapidly metabolized and its androgen receptor activity in the hypothalamus-pituitary axis is attenuated by its high peripheral binding; at doses of 100 mg/day or more, suppression becomes clinically relevant.

What Proviron Does

• SHBG displacement increases bioavailable testosterone — mesterolone's highest-affinity binding target is SHBG, not the androgen receptor; by competitively binding SHBG, mesterolone displaces testosterone from its bound (inactive) state; the result is a higher free testosterone fraction without any change in total testosterone production or injection dose; in practical terms, adding 50 mg/day of Proviron to a testosterone cycle can meaningfully increase the effective androgenic output of the same testosterone dose; this mechanism is most pronounced when SHBG is elevated (which occurs naturally with age, caloric restriction, and some oral AAS)
• Mild anti-estrogenic activity — mesterolone exerts a weak inhibitory effect on aromatase, the enzyme responsible for converting testosterone to estradiol; it also competes with estrogen at some receptor sites; the effect is subtle — Proviron is not a substitute for an aromatase inhibitor in a high-dose testosterone cycle — but in low-testosterone, dry-stack protocols (Primobolan or Masteron base with low test), it contributes meaningful estrogen management without the over-suppression risk of a potent AI; this makes it useful in pre-contest phases where E2 must be controlled but not eliminated
• Androgenic support for libido and wellbeing on cycle — mesterolone's strong androgenic tissue activity at the peripheral level (skin, scalp, prostate) supports libido, sexual function, and mood; these effects are particularly relevant in cycles that run low test with dry compounds (Primobolan, Masteron, Trenbolone) where endogenous testosterone is suppressed and the aromatizing testosterone base is intentionally minimized; Proviron fills the androgenic deficit at target tissues without contributing to estrogen load
• Muscle tissue hardness and density — the absence of water retention combined with androgenic tissue activity produces a drier, denser appearance that is valued in pre-contest protocols; mesterolone does not add lean mass in the same way anabolic compounds do; rather it improves the quality and appearance of existing lean tissue by eliminating fluid and increasing free androgen activity at target tissues; this effect compounds with other dry compounds in the stack
• Extended oral use without hepatic strain — because mesterolone is not 17α-alkylated, it can be run for the full cycle duration (12–16 weeks) without the liver enzyme elevation, cholestasis risk, or mandatory cycle-length ceiling of alkylated oral AAS; ALT/AST monitoring is still standard practice, but the expected hepatic impact is negligible at 25–75 mg/day; this is a meaningful practical advantage over Anavar or Winstrol when continuous oral DHT activity is needed across a long cycle

Who It's For

• Athletes running any testosterone-based cycle who want to maximize free testosterone output — Proviron is most commonly used as a permanent stack addition on testosterone cycles; at 25–50 mg/day it consistently improves the free testosterone fraction, libido, and mood without adding meaningful side effects or cost; this benefit applies regardless of the cycle's primary goal; it is particularly useful for users who notice SHBG creeping up mid-cycle (common on caloric restriction or when oral AAS are included) and want to counteract the reduction in free testosterone without adjusting the testosterone dose
• Users running dry, low-estrogen stacks who need androgenic and anti-estrogenic support without a full AI — in pre-contest stacks built around Primobolan, Masteron, or Parabolan with a low testosterone base (200–300 mg/week), estrogen levels are already naturally low; adding a standard AI dose risks over-suppression (E2 below 10–15 pg/mL causes joint pain, fatigue, and libido crash); Proviron at 25–50 mg/day provides mild estrogen management through SHBG and weak aromatase competition without the hard E2 suppression of Aromasin or Letrozole; it also covers the androgenic deficit that arises when the testosterone base is intentionally kept low
• What differentiates Proviron from similar alternatives: compared to Masteron 100 (injectable drostanolone propionate), Proviron delivers the same SHBG-binding and mild anti-estrogenic mechanism in oral form without injections; Masteron is more potent androgenically and is a primary stack compound in its own right — Proviron is a support compound; compared to Aromasin (exemestane), Proviron manages estrogen through a completely different mechanism (SHBG displacement + weak aromatase competition vs. irreversible aromatase inhibition); Aromasin is appropriate when E2 is genuinely elevated and requires meaningful reduction; Proviron is appropriate when SHBG binding and mild anti-estrogenic activity are needed without aggressive E2 suppression; compared to Anavar 50, Proviron has much weaker anabolic activity but superior SHBG binding, no hepatic ceiling, and zero water retention
• Users who should choose something else: Proviron is not a mass-building compound; users whose primary goal is lean mass accumulation should select a primary anabolic compound and potentially add Proviron as a support layer; users with clinically elevated E2 requiring meaningful reduction need an aromatase inhibitor, not Proviron alone; users who cannot commit to twice-daily oral dosing should consider an injectable DHT-based option instead

Proviron vs Alternatives

Combinations

Side Effects & Management

Bloodwork Monitoring

PCT

At standard doses of 25–50 mg/day, mesterolone does not meaningfully suppress endogenous LH and FSH and does not require dedicated PCT management beyond the primary AAS cycle's protocol. PCT timing and SERM selection are determined by the suppressive compounds in the stack (testosterone ester, 19-nors, etc.) — not by Proviron. At doses of 75–100 mg/day sustained over a full cycle, Proviron's suppression contribution becomes more relevant and should be factored into PCT planning.

Practical Summary

References